Cicletanine (DrugBank: Cicletanine)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 86 | Pulmonary arterial hypertension | 6 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2008-007455-26-AT (EUCTR) | 21/01/2010 | 10/03/2009 | A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects with Pulmonary Arterial Hypertension | A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects with Pulmonary Arterial Hypertension | Pulmonary hypertension (PH) is a serious and life-threatening disease of the pulmonary vasculature, characterized by profound vasoconstriction and an abnormal proliferation of smooth muscle cells in the walls of the pulmonary arteries. MedDRA version: 13.1;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders | Product Name: Cicletanine hydrochloride Product Code: NA Product Name: Cicletanine hydrochloride Product Code: NA | Gilead Sciences, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 160 | Phase 2 | United Kingdom;Germany;Belgium;Spain;Austria | ||
| 2 | EUCTR2008-007455-26-GB (EUCTR) | 31/12/2009 | 14/04/2009 | A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects with Pulmonary Arterial Hypertension | A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects with Pulmonary Arterial Hypertension | Pulmonary hypertension (PH) is a serious and life-threatening disease of the pulmonary vasculature, characterized by profound vasoconstriction and an abnormal proliferation of smooth muscle cells in the walls of the pulmonary arteries. MedDRA version: 13.1;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders | Product Name: Cicletanine hydrochloride Product Code: Not applicable Product Name: Cicletanine hydrochloride Product Code: Not applicable | Gilead Sciences, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 160 | Phase 2 | Spain;Belgium;Austria;Germany;United Kingdom | ||
| 3 | EUCTR2008-007455-26-ES (EUCTR) | 28/09/2009 | 23/04/2009 | A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects with Pulmonary Arterial HypertensionEstudio en fase II , de asignación aleatoria, doblemente ciego, controlado con placebo y multicéntrico. Estudio de búsqueda de dosis con cicletanina en sujetos con hipertensión arterial pulmonar | A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects with Pulmonary Arterial HypertensionEstudio en fase II , de asignación aleatoria, doblemente ciego, controlado con placebo y multicéntrico. Estudio de búsqueda de dosis con cicletanina en sujetos con hipertensión arterial pulmonar | Pulmonary hypertension (PH) is a serious and life-threatening disease of the pulmonary vasculature, characterized by profound vasoconstriction and an abnormal proliferation of smooth muscle cells in the walls of the pulmonary arteries.La hipertensión pulmonar (PH) es una enfermedad grave y potencialmente mortal de la vasculatura pulmonar, caracterizada por una vasoconstricción profunda y una proliferación anómala de células musculares lisas en las paredes de las arterías pulmonares MedDRA version: 9.1;Level: LLT;Classification code 10064911;Term: Pulmonary arterial hypertension | Product Name: Cicletanine hydrochloride Product Name: Cicletanine hydrochloride | Gilead Sciences, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 160 | Phase 2 | United Kingdom;Germany;Belgium;Spain;Austria | ||
| 4 | EUCTR2008-007455-26-DE (EUCTR) | 13/08/2009 | 23/03/2009 | Cicletanine Phase II for Pulmonary Arterial Hypertension | A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects with Pulmonary Arterial Hypertension | Pulmonary hypertension (PH) is a serious and life-threatening disease of the pulmonary vasculature, characterized by profound vasoconstriction and an abnormal proliferation of smooth muscle cells in the walls of the pulmonary arteries. MedDRA version: 13.1;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Product Name: Cicletanine hydrochloride Product Name: Cicletanine hydrochloride | Gilead Sciences, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 160 | Phase 2 | United States;Mexico;Canada;Spain;Belgium;Austria;Australia;Israel;Germany;United Kingdom | ||
| 5 | EUCTR2008-007455-26-BE (EUCTR) | 08/06/2009 | 30/03/2009 | A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects with Pulmonary Arterial Hypertension | A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects with Pulmonary Arterial Hypertension | Pulmonary hypertension (PH) is a serious and life-threatening disease of the pulmonary vasculature, characterized by profound vasoconstriction and an abnormal proliferation of smooth muscle cells in the walls of the pulmonary arteries. MedDRA version: 13.1;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders | Product Name: Cicletanine hydrochloride Product Name: Cicletanine hydrochloride | Gilead Sciences, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 160 | Phase 2 | Spain;Belgium;Austria;Germany;United Kingdom | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT00832507 (ClinicalTrials.gov) | January 2009 | 29/1/2009 | Study of Cicletanine for Pulmonary Arterial Hypertension (PAH) | A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension | Pulmonary Arterial Hypertension | Drug: Cicletanine;Drug: Cicletanine Placebo | Gilead Sciences | NULL | Terminated | 16 Years | 70 Years | Both | 162 | Phase 2 | United States;Australia;Austria;Belgium;Canada;Germany;Israel;Mexico;Spain;United Kingdom |